New Insights into the Heparan Sulfate Proteoglycan-binding Activity of Apolipoprotein E*
暂无分享,去创建一个
Ishan Capila | Fanyu Zhou | S. Wehrli | C. P. Libeu | K. Weisgraber | I. Capila | M. Hernáiz | M. Phillips | Karl H. Weisgraber | Michael C. Phillips | Sissel Lund-Katz | R. Linhardt | Suzanne Wehrli | Y. Newhouse | S. Lund-Katz | Clare Peters Libeu | Maria J. Hernáiz | Robert J. Linhardt | Robert L. Raffaı̈ | Yvonne M. Newhouse | R. Raffaı̈ | Fanyu Zhou | M. Hernaiz
[1] Gérard Siest,et al. Heparin specifically inhibits binding of apolipoprotein E to amyloid β-peptide , 2000, Neuroscience Letters.
[2] I. Fuki,et al. Cell-surface heparan sulfate proteoglycans: dynamic molecules mediating ligand catabolism , 1997, Current opinion in lipidology.
[3] R. Mahley,et al. [13] Isolation and characterization of apolipoprotein E , 1986 .
[4] E A Merritt,et al. Raster3D: photorealistic molecular graphics. , 1997, Methods in enzymology.
[5] H. Conrad. Structures of Heparinoids , 1998 .
[6] Sean Parkin,et al. Novel mechanism for defective receptor binding of apolipoprotein E2 in type III hyperlipoproteinemia , 1996, Nature Structural Biology.
[7] M C Phillips,et al. A 13C NMR characterization of lysine residues in apolipoprotein B and their role in binding to the low density lipoprotein receptor. , 1988, The Journal of biological chemistry.
[8] Yan Xu,et al. Delayed catabolism of apoB-48 lipoproteins due to decreased heparan sulfate proteoglycan production in diabetic mice. , 2000, The Journal of clinical investigation.
[9] R. Mahley,et al. Apolipoprotein E: from atherosclerosis to Alzheimer's disease and beyond. , 1999, Current opinion in lipidology.
[10] E. Masliah,et al. LDL receptor‐related protein (LRP) in Alzheimer's disease: Towards a unified theory of pathogenesis , 2000, Microscopy research and technique.
[11] M. Höök,et al. Biosynthesis of heparin. Assay and properties of the microsomal N-acetyl-D-glucosaminyl N-deacetylase. , 1980, The Journal of biological chemistry.
[12] K. Weisgraber. Apolipoprotein E: structure-function relationships. , 1994, Advances in protein chemistry.
[13] L. Kjellén,et al. Reduced Sulfation of Liver Heparan Sulfate in Experimentally Diabetic Rats , 1983, Diabetes.
[14] G. Siest,et al. Kinetics of apolipoprotein E isoforms‐binding to the major glycosaminoglycans of the extracellular matrix , 1999, FEBS letters.
[15] Suzanne Wehrli,et al. Effects of Lipid Interaction on the Lysine Microenvironments in Apolipoprotein E* , 2000, The Journal of Biological Chemistry.
[16] L. Andersson,et al. Purification of antithrombin III by affinity chromatography , 1974 .
[17] R. Mahley,et al. Binding of arginine-rich (E) apoprotein after recombination with phospholipid vesicles to the low density lipoprotein receptors of fibroblasts. , 1979, The Journal of biological chemistry.
[18] R. Mahley,et al. Remnant lipoprotein metabolism: key pathways involving cell-surface heparan sulfate proteoglycans and apolipoprotein E. , 1999, Journal of lipid research.
[19] R. Mahley,et al. Apolipoprotein E: far more than a lipid transport protein. , 2000, Annual review of genomics and human genetics.
[20] A. Oldberg,et al. Cell-surface heparan sulfate. Mechanisms of proteoglycan-cell association. , 1980, The Journal of biological chemistry.
[21] I. Goldberg,et al. Oligosaccharide sequences of endothelial cell surface heparan sulfate proteoglycan with affinity for lipoprotein lipase. , 1994, The Journal of biological chemistry.
[22] R. Mahley,et al. Pathogenesis of type III hyperlipoproteinemia (dysbetalipoproteinemia). Questions, quandaries, and paradoxes. , 1999, Journal of lipid research.
[23] R. Williams,et al. Williams Textbook of endocrinology , 1985 .
[24] R. Mahley,et al. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. , 1994, The Journal of biological chemistry.
[25] R. Mahley,et al. The receptor-binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments. , 1983, The Journal of biological chemistry.
[26] P. Kraulis. A program to produce both detailed and schematic plots of protein structures , 1991 .
[27] R. Mahley,et al. Human apolipoprotein E. Determination of the heparin binding sites of apolipoprotein E3. , 1986, The Journal of biological chemistry.
[28] F. Young. Biochemistry , 1955, The Indian Medical Gazette.
[29] H. Rauvala,et al. Neurite Outgrowth in Brain Neurons Induced by Heparin-binding Growth-associated Molecule (HB-GAM) Depends on the Specific Interaction of HB-GAM with Heparan Sulfate at the Cell Surface (*) , 1996, The Journal of Biological Chemistry.
[30] M. Saraste,et al. FEBS Lett , 2000 .
[31] M. Tremblay,et al. Identification and characterization of a novel apolipoprotein E variant, apolipoprotein E3' (Arg136-->His): association with mild dyslipidemia and double pre-beta very low density lipoproteins. , 1995, Journal of lipid research.
[32] U. Beisiegel,et al. Apolipoprotein E isoforms and rare mutations: parallel reduction in binding to cells and to heparin reflects severity of associated type III hyperlipoproteinemia. , 1995, Journal of lipid research.
[33] B. Rupp,et al. Interaction of the N-terminal domain of apolipoprotein E4 with heparin. , 2001, Biochemistry.
[34] K. Weisgraber,et al. The functional characteristics of a human apolipoprotein E variant (cysteine at residue 142) may explain its association with dominant expression of type III hyperlipoproteinemia. , 1992, The Journal of biological chemistry.
[35] R. Mahley,et al. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. , 1988, Science.
[36] R. Mahley,et al. Stable Expression and Secretion of Apolipoproteins E3 and E4 in Mouse Neuroblastoma Cells Produces Differential Effects on Neurite Outgrowth (*) , 1995, The Journal of Biological Chemistry.
[37] D. Agard,et al. Human apolipoprotein E. Role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. , 1994 .
[38] M. Forster,et al. N.m.r. and molecular-modelling studies of the solution conformation of heparin. , 1993, The Biochemical journal.
[39] Wayne A. Hendrickson,et al. Structure of a heparin-linked biologically active dimer of fibroblast growth factor , 1998, Nature.
[40] R. Schutgens. The metabolic and molecular bases of inherited disease, seventh edition—3-volume set Edited by Charles R. Scriver, Arthur L. Beaudet, William S. Sly, and David Valle. New York, McGraw-Hill, 1995, $285.84 (xxxvi + 4605 pages and 93-page index), ISBN 0-07909-826-6 , 1995, Trends in Endocrinology & Metabolism.
[41] K. Yoshida,et al. Heparan sulfate isomers in cerebral arteries of Japanese women with aging and with atherosclerosis--heparitinase and high-performance liquid chromatography determinations. , 1997, Atherosclerosis.
[42] D. Holtzman,et al. Low density lipoprotein receptor-related protein mediates apolipoprotein E-dependent neurite outgrowth in a central nervous system-derived neuronal cell line. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[43] G. Orr. The use of the 2-iminobiotin-avidin interaction for the selective retrieval of labeled plasma membrane components. , 1981, The Journal of biological chemistry.
[44] D. Rees,et al. Diversity does make a difference: fibroblast growth factor-heparin interactions. , 1998, Current opinion in structural biology.
[45] G. Giménez-Gallego,et al. Common Binding Sites for β-Amyloid Fibrils and Fibroblast Growth Factor-2 in Heparan Sulfate from Human Cerebral Cortex* , 1999, The Journal of Biological Chemistry.
[46] R. Mahley,et al. Site-specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. , 1988, The Journal of biological chemistry.
[47] M. Lyon,et al. Liver heparan sulfate structure. A novel molecular design. , 1994, The Journal of biological chemistry.
[48] R. Mahley,et al. The receptor-binding domain of human apolipoprotein E. Monoclonal antibody inhibition of binding. , 1983, The Journal of biological chemistry.
[49] K. Weisgraber,et al. Conformational Reorganization of the Four-helix Bundle of Human Apolipoprotein E in Binding to Phospholipid* , 2000, The Journal of Biological Chemistry.
[50] O. H. Lowry,et al. Protein measurement with the Folin phenol reagent. , 1951, The Journal of biological chemistry.
[51] J. Hirsh,et al. Heparin Binding Proteins Contribution to Heparin Rebound After Cardiopulmonary Bypass , 1993, Circulation.
[52] K. Weisgraber,et al. Functional characterization of apolipoprotein E isoforms overexpressed in Escherichia coli. , 1999, Protein expression and purification.
[53] W. März,et al. Apolipoprotein E2 (Arg136 --> Cys) mutation in the receptor binding domain of apoE is not associated with dominant type III hyperlipoproteinemia. , 1998, Journal of lipid research.
[54] T. Mazzone,et al. Cell Surface Proteoglycans Modulate Net Synthesis and Secretion of Macrophage Apolipoprotein E* , 1996, The Journal of Biological Chemistry.
[55] R. Rosenberg. The Molecular and Genetic Basis of Neurological Disease , 1997 .
[56] M. Höök,et al. Distribution of sulphate and iduronic acid residues in heparin and heparan sulphate. , 1974, The Biochemical journal.
[57] D C Rees,et al. Heparin Structure and Interactions with Basic Fibroblast Growth Factor , 1996, Science.
[58] M. Salmivirta,et al. Age-dependent Modulation of Heparan Sulfate Structure and Function* , 1998, The Journal of Biological Chemistry.
[59] U. Lindahl,et al. Domain Structure of Heparan Sulfates from Bovine Organs* , 1996, The Journal of Biological Chemistry.
[60] I. Pettersson,et al. Decreased activity of the heparan sulfate-modifying enzyme glucosaminyl N-deacetylase in hepatocytes from streptozotocin-diabetic rats. , 1991, The Journal of biological chemistry.